Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

The rationale for the study under discussion is that the experience level of the operating surgeon is a potential factor affecting the outcomes of all ophthalmic procedures, including ISBCS

Resident surgeons perform ISBCS with similar safety and accuracy as consultants

Robert C. Sergott, MD, is chief of the Neuro-Ophthalmology Service at Wills Eye Hospital in Philadephia, Pennsylvania.

Videos

This noninvasive imaging tool reveals early brain pathology through the eye, promising faster and more accurate diagnoses as highlighted at the 2025 International SPECTRALIS Symposium – and Beyond.

FLIO and the brain: Making the invisible visible with Robert Sergott, MD

Karl Csaky, MD, PhD, is a vitreoretinal specialist serving as the chief executive and medical officer at the Retina Foundation of the Southwest in Dallas, Texas.

Findings presented at the Heidelberg 2025 International SPECTRALIS Symposium — And Beyond suggest detailed structural data could better inform therapeutic targeting and monitoring.

Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD

SriniVas R. Sadda, MD, is the Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA) Geffen School of Medicine. He is the immediate past President of the Doheny Eye Institute.

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – and Beyond.

SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Surgery, chemotherapy, and radiation are three options for the treatment of malignant tumors today. Surgery is a therapy that dates back to the Stone Age; chemotherapy is approximately 50 years old. The topic of this month's ophthalmic vignette pertains to the discovery of radiation.

Curie's Discovery of Radioactivity Helps Ophthalmic Field

Curie's Discovery of Radioactivity Helps Ophthalmic Field

Newsletter